Expert Analysis From AASLD: Updates in HBV Treatment

[Guest guest]

OFFICIAL CONFERENCE COVERAGE

2010 Annual Meeting of the American Association for the Study of Liver Diseases

CCO is the official provider of online Conference Coverage of The Liver Meeting®

2010.

To:

CCO member

From:

Norah Terrault, MD, MPH

University of California, San Francisco

San Francisco, California

Subject:

CME-Certified Expert Analysis From AASLD 2010

Click to Access:

Updates in HBV Treatment

While attending the Annual AASLD meeting in Boston, I met with S. F. Lok,

MD, and Marcellin, MD, to review some of the most noteworthy new data on

HBV treatment. Our discussion is now available on the Clinical Care Options Web

site as a CME-certified Expert Analysis. Select topics include:

Study 103: 4 Years of Tenofovir in Patients With HBeAg-Positive Chronic HBV

Infection

Study 102: 4 Years of Tenofovir in Patients With HBeAg-Negative Chronic HBV

Infection

Prevalence of Proximal Tubular Dysfunction During Tenofovir Therapy for Chronic

HBV Infection

NEPTUNE: Peginterferon alfa-2a 90 µg/week vs 180 µg/week for 24 vs 48 Weeks in

Patients With HBeAg-Positive HBV Infection

PegBeLiver: Peginterferon alfa-2a for 48 vs 96 Weeks in Patients With

HBeAg-Negative Genotype D HBV

Peginterferon alfa-2b for 24 vs 48 Weeks in Patients With HBeAg-Positive HBV

Infection

Impact of Mode of Delivery on Perinatal HBV Transmission Risk

Telbivudine Treatment During Late Pregnancy for Prevention of Perinatal HBV

Transmission

Incidence and Correlates of Liver Outcomes Among Patients With Chronic HBV

Infection

To review this CME-certified Expert Analysis, click here.

This Expert Analysis is located online at:

http://clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202010.aspx

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and

Clinical Care Options, LLC.

Release date: December 17, 2010

Expiration date: December 16, 2011

Supported by educational grants from Bristol-Myers Squibb, Janssen

Pharmaceutical Companies of & , Merck, and Vertex.

PARTNERSHIP INFORMATION

CCO is the official provider of online conference coverage of The Liver Meeting®

2010. For more information about the AASLD, go to http://www.aasld.org.

Clinical Care Options Hepatitis

GET MORE FROM CCO

Hepatitis Slide Library

Review hundreds of slidesets featuring the latest data on hepatitis management.

Then download PowerPoint files for use in your own noncommercial talks.

Click here to start.

Conference Coverage

Journal Options

Management Series

Treatment Updates

Interactive Cases

Live Meetings

RSS / Podcasts

My CME Tracker

Free Bookstore

Slide Downloads

Copyright 2011 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

Not a member yet? Click here

[Guest guest]

OFFICIAL CONFERENCE COVERAGE

2010 Annual Meeting of the American Association for the Study of Liver Diseases

CCO is the official provider of online Conference Coverage of The Liver Meeting®

2010.

To:

CCO member

From:

Norah Terrault, MD, MPH

University of California, San Francisco

San Francisco, California

Subject:

CME-Certified Expert Analysis From AASLD 2010

Click to Access:

Updates in HBV Treatment

While attending the Annual AASLD meeting in Boston, I met with S. F. Lok,

MD, and Marcellin, MD, to review some of the most noteworthy new data on

HBV treatment. Our discussion is now available on the Clinical Care Options Web

site as a CME-certified Expert Analysis. Select topics include:

Study 103: 4 Years of Tenofovir in Patients With HBeAg-Positive Chronic HBV

Infection

Study 102: 4 Years of Tenofovir in Patients With HBeAg-Negative Chronic HBV

Infection

Prevalence of Proximal Tubular Dysfunction During Tenofovir Therapy for Chronic

HBV Infection

NEPTUNE: Peginterferon alfa-2a 90 µg/week vs 180 µg/week for 24 vs 48 Weeks in

Patients With HBeAg-Positive HBV Infection

PegBeLiver: Peginterferon alfa-2a for 48 vs 96 Weeks in Patients With

HBeAg-Negative Genotype D HBV

Peginterferon alfa-2b for 24 vs 48 Weeks in Patients With HBeAg-Positive HBV

Infection

Impact of Mode of Delivery on Perinatal HBV Transmission Risk

Telbivudine Treatment During Late Pregnancy for Prevention of Perinatal HBV

Transmission

Incidence and Correlates of Liver Outcomes Among Patients With Chronic HBV

Infection

To review this CME-certified Expert Analysis, click here.

This Expert Analysis is located online at:

http://clinicaloptions.com/Hepatitis/Conference%20Coverage/AASLD%202010.aspx

Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and

Clinical Care Options, LLC.

Release date: December 17, 2010

Expiration date: December 16, 2011

Supported by educational grants from Bristol-Myers Squibb, Janssen

Pharmaceutical Companies of & , Merck, and Vertex.

PARTNERSHIP INFORMATION

CCO is the official provider of online conference coverage of The Liver Meeting®

2010. For more information about the AASLD, go to http://www.aasld.org.

Clinical Care Options Hepatitis

GET MORE FROM CCO

Hepatitis Slide Library

Review hundreds of slidesets featuring the latest data on hepatitis management.

Then download PowerPoint files for use in your own noncommercial talks.

Click here to start.

Conference Coverage

Journal Options

Management Series

Treatment Updates

Interactive Cases

Live Meetings

RSS / Podcasts

My CME Tracker

Free Bookstore

Slide Downloads

Copyright 2011 Clinical Care Options, LLC. All rights reserved. 1894 Preston

White Drive, Suite 110, Reston, VA 20191-5433

Not a member yet? Click here